Rheumatoid Arthritis (RA)

RA is an autoimmune and inflammatory disease where the immune system attacks healthy cells, causing inflammation and painful swelling in the affected parts of the body.\(^1\)

Management of RA includes a combination of clinician exams, laboratory work, and various combinations of medications that help slow disease progression and prevent joint deformity. This management approach plays a vital role in determining disease severity and achieving low disease activity or near remission with few or no RA symptoms, which is the goal of therapy.\(^1\)

### TREATMENT

Management of RA includes a combination of clinician exams, laboratory work, and various combinations of medications that help slow disease progression and prevent joint deformity. This management approach plays a vital role in determining disease severity and achieving low disease activity or near remission with few or no RA symptoms, which is the goal of therapy.\(^1\)

### SHIELDS 2022 RA OUTCOMES

<table>
<thead>
<tr>
<th>Percentage</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>52%</td>
<td>52% of RA patients IMPROVED their RAPID3 score resulting in positive treatment outcomes</td>
</tr>
<tr>
<td>93%</td>
<td>93% of patients reported their condition has improved or has been stable since onboarded with Shields</td>
</tr>
<tr>
<td>79%</td>
<td>79% of patients reported no missed days of planned activity, school, or work</td>
</tr>
</tbody>
</table>

### SHIELDS NETWORK OUTCOMES*

1.5 MILLION RA PATIENTS IN THE U.S.\(^2\)

### RAPID3:

Measuring disease activity and patient response enables healthcare teams to evaluate the success of RA treatments and identify needed changes. These scores support a collaborative effort among the patient care team, facilitating shared decisions to improve patient health outcomes.

### DISEASE CONTROL:

Tools like RAPID3, supplemented by patient-reported outcomes (PROs), provide valuable insights into disease management from patients' perspectives. This contributes to a holistic understanding of patient experiences, ensuring optimum patient care and enhancing patient outcomes.

### ABSENTEEISM:

Comprehensive care requires a thorough understanding of disease management. Absenteeism measurement is a vital component, providing insights into disease burden and quality of life effects, leading to enhanced care, improved quality of life, and reduced costs.

### 3 Common Barriers to the Treatment & Management of Rheumatoid Arthritis

1. Lack of financial resources
2. Lack understanding of disease progression
3. Medication adherence
Rheumatoid Arthritis (RA)

Our proven care model breaks down barriers to care to optimize patient outcomes

Shields Health Solutions’ dedicated clinical team of pharmacists, liaisons and patient support advocates, engages patients and their families to help educate, coordinate care and ensure patients receive specialty medication without significant delays.

**Engage**
Our clinical team engages with patients at the clinic and through telehealth appointments.

**Intervene**
Clinical pharmacists intervene to improve the patient’s care plan when drug interactions, related side effects, barriers to adherence or other instances are identified.

**Coordinate**
Liaisons investigate patient benefits, complete prior authorizations and identify financial assistance, minimizing barriers to optimal therapy.

**Enhance**
Through clinical pharmacist interventions, we can enhance patient care by providing support, education, and optimizing therapy when challenges arise, and treatment goals are not met.

**Renew**
Ongoing interactions beyond refills; proactively identify opportunities to improve patient care and outcomes at each touchpoint.

---

**FAs/PAs Completed (YTD)**
Clinical staff utilizes their time to focus on patient care.

- $54K

**Net Promoter Score**
Patients are satisfied with the pharmacy service.

- 83.6

**Average Provider Score**
Providers have a seamless experience.

- 90.4%

**Patient Reported Treatment Efficacy**
Percentage of RA patients who report they feel very well or well with how their specialty medication is helping them with RA.

- 92%

---

**Shields Health Solutions’ Care Continuum**

**Engage**
Our clinical team engages with patients at the clinic and through telehealth appointments.

**Intervene**
Clinical pharmacists intervene to improve the patient’s care plan when drug interactions, related side effects, barriers to adherence or other instances are identified.

**Coordinate**
Liaisons investigate patient benefits, complete prior authorizations and identify financial assistance, minimizing barriers to optimal therapy.

**Enhance**
Through clinical pharmacist interventions, we can enhance patient care by providing support, education, and optimizing therapy when challenges arise, and treatment goals are not met.

**Renew**
Ongoing interactions beyond refills; proactively identify opportunities to improve patient care and outcomes at each touchpoint.

**FAs/PAs Completed (YTD)**
Clinical staff utilizes their time to focus on patient care.

- $54K

**Net Promoter Score**
Patients are satisfied with the pharmacy service.

- 83.6

**Average Provider Score**
Providers have a seamless experience.

- 90.4%

**Patient Reported Treatment Efficacy**
Percentage of RA patients who report they feel very well or well with how their specialty medication is helping them with RA.

- 92%

---

**Financial Assistance**
Secured in 2022.

- $10M

**Cost Avoidance**
Maximize cost avoidance.

- $6M per year

**Med Adherence**
(Proportion of Days Covered)
Patients receive and take medications on time.

- 91%

---

**Clinical Interventions (Total by Clinic)**
Preemptively adjust patient medication to prevent complications.

- >3K

**Average Time to Therapy**
Patients start medication on time.

- 2 days

**Copay**
Patients can access and afford treatment.

- $10

---

1 Rheumatoid Arthritis (RA) | Arthritis | CDC. Accessed 5/14/21

*All metrics are reflective of data collected in 2022.*

*Shields Health Solutions Network includes data from a collective of member health systems that partner with Shields to elevate an integrated specialty pharmacy model.*